Lataa...
Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies
Immunotherapy, especially based on chimeric antigen receptor (CAR) T cells, has achieved prominent success in the treatment of hematological malignancies. However, approximately 30-50% of patients will have disease relapse following remission after receiving CD19-targeting CAR-T cells, with failure...
Tallennettuna:
| Julkaisussa: | Biomed Res Int |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Hindawi
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7603553/ https://ncbi.nlm.nih.gov/pubmed/33150182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8765028 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|